Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.42 |
| ▸ | PRKCZ | Q05513 | 5/20 | 0.38 |
| ▸ | PRKD2 | Q9BZL6 | 4/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CCR6 | P51684 | 3/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.37 |
| ▸ | GPR6 | P46095 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2424533 | 0.91 | ROCK2 (0.43) | ROCK2PRKCZPRKD2CCNA2CDK2 | |
| SCHEMBL13087712 | 0.90 | ROCK2 (0.45) | ROCK2PRKCZPRKD2ROCK1CCNA2 | |
| SCHEMBL13089969 | 0.89 | ROCK2 (0.43) | ROCK2PRKCZPRKD2CCNA2CDK2 | |
| SCHEMBL13087361 | 0.87 | ROCK2 (0.46) | ROCK2PRKCZPRKD2IRAK4MCHR1 | |
| SCHEMBL13087305 | 0.87 | ROCK2 (0.46) | ROCK2PRKCZPRKD2IRAK4MCHR1 | |
| SCHEMBL13087153 | 0.86 | CCR6 (0.51) | ROCK2PRKCZPRKD2CCNA2CDK2 | |
| SCHEMBL13090008 | 0.86 | CCR6 (0.51) | ROCK2CCNA2CDK2CNR1CCR6 | |
| SCHEMBL13087245 | 0.86 | CCR6 (0.44) | ROCK2CCNA2CDK2CCR6BRD4 | |
| SCHEMBL13087792 | 0.86 | PIK3CA (0.42) | ROCK2PRKCZPRKD2CCNA2CDK2 | |
| SCHEMBL13090042 | 0.85 | CNR1 (0.37) | ROCK2PRKCZPRKD2ROCK1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | RELA, NFKBIA, NFKB2 | ROCK2 1065/4885PRKCZ 272/4885PRKD2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.